IP Library › Granted Patent US 8,795,666
Granted Patent B2
US 8,795,666 · App. 13/762,133 · Granted Aug 5, 2014

Antagonists of IL-23P19 for treatement of atopic dermatitis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,795,666
App. No.
13/762,133
Granted
Aug 5, 2014
Kind
B2
Abstract

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (4)

1. A method of treating a human subject experiencing atopic dermatitis comprising administering an effective amount of an antagonist antibody that specifically binds to a polypeptide comprising the sequence of SEQ ID NO: 6, or an antigen binding fragment thereof.

2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody or antigen binding fragment thereof.

3. The method of claim 1 , wherein the antibody or antigen binding fragment thereof is a humanized antibody or antigen binding fragment thereof.

4. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′) 2 fragment.